Charles River Laboratories (CRL) Climbs +24.6% in 30 Days on Strong Q2 Results
Key Takeaways
- CRL shares climbed roughly 24.6% over the trailing 30 days, rising from about $234 to approximately $292.
- The advance was driven by stronger-than-expected second-quarter 2026 results and raised full-year guidance.
- Discovery and Safety Assessment (DSA) bookings hit a near four-year high, with a net book-to-bill ratio of 1.19x.
- Analyst sentiment turned more constructive, lifting the consensus rating to "Strong Buy" alongside several price-target increases.
- Over the trailing quarter, the stock has gained more than 60%, extending a multi-month recovery rally.
Charles River Laboratories (CRL) Company Overview and Market Position
Charles River Laboratories International, Inc., headquartered in Wilmington, Massachusetts, is a leading global provider of drug discovery and early-stage development services for the pharmaceutical and biotechnology industries. The company operates through three reporting segments: Discovery and Safety Assessment (DSA), Research Models and Services (RMS), and Manufacturing. CRL is widely recognized for its research models—including non-human primates and small research models—and its regulated preclinical and safety assessment testing services, which support clients from early discovery through clinical development.
Investors follow CRL closely because its results serve as a read-through on biopharmaceutical research-and-development spending. The company's competitive advantages include deep scientific expertise, a vertically integrated non-human primate supply chain strengthened by acquisitions of suppliers in Cambodia and Mauritius, global scale, and long-standing relationships with major pharmaceutical clients. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CRL Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, CRL shares advanced from a closing price of $234.12 on August 4, 2026, to approximately $291.60 at the latest available session, a gain of about 24.6%. The sharpest single-day move occurred on August 5, when shares jumped roughly 11% following the company's second-quarter earnings report and updated guidance.
The near-term gain is part of a broader, longer-running rally. Over the trailing quarter, CRL has climbed from around $180 per share in early June to roughly $292, an increase of more than 60%. This sustained uptrend reflects improving fundamentals rather than a one-off catalyst, with the stock repeatedly reaching new 52-week highs along the way.
What Drove CRL Stock Price in the Last 30 Days
The dominant catalyst was CRL's second-quarter 2026 earnings report, released on August 5. The company posted non-GAAP earnings of $3.02 per share, beating the consensus estimate of $2.74 by about 17.6%. Revenue of $1.004 billion declined 2.7% year over year on a reported basis but rose 0.1% organically—marking the company's first organic revenue growth since the third quarter of 2023. Revenue also exceeded the consensus estimate of roughly $975.7 million.
Management raised its full-year 2026 outlook, lifting non-GAAP EPS guidance to a range of $11.15 to $11.45 from $10.80 to $11.30 and increasing its organic revenue growth forecast to 0% to 1% from a prior range of negative 1.5% to negative 0.5%. The DSA segment, CRL's largest, returned to organic growth, while net bookings rose 12.6% sequentially to $701 million, backlog reached $1.97 billion, and the net book-to-bill ratio improved to 1.19x—the highest level in nearly four years.
Analyst reaction reinforced the move. TD Cowen maintained a Buy rating and raised its price target to $300 from $235, citing stronger preclinical demand. Across 16 analysts, the consensus rating improved to "Strong Buy," reflecting 11 Strong Buy, 2 Moderate Buy, and 3 Hold ratings. Broader investor interest in artificial-intelligence-linked drug discovery, including CRL's collaboration with Eli Lilly (LLY) on its TuneLab platform, also supported sentiment.
What Drove CRL Stock Performance Over the Last Quarter
The quarterly advance reflects a multi-month recovery narrative built on strengthening biopharmaceutical demand. Throughout the period, CRL reported improving DSA booking trends, with the book-to-bill ratio remaining above 1.0x for three consecutive quarters, signaling that new work is outpacing completed revenue.
Portfolio optimization has also played a central role. The company completed divestitures of its CDMO and Cell Solutions businesses and certain European Discovery Services sites in May 2026, streamlining operations around core regulated testing capabilities and lifting margins. These actions contributed to a sequential operating-margin improvement of 420 basis points in the second quarter. Ongoing share repurchases—including $100 million in the second quarter—provided additional support. The result has been a steady climb from roughly $156 per share in late May to recent highs near $292.
CRL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will be watching whether CRL's improving DSA bookings convert into sustained revenue growth and stronger margins. Management has indicated that lower Cambodian non-human primate sourcing costs should begin benefiting DSA margins in the third quarter, with a larger contribution in the fourth quarter. The RMS segment remains a point of caution, pressured by flat National Institutes of Health budgets and slower grant processing that have constrained academic and government spending.
Additional factors to monitor include the pace of biopharmaceutical R&D spending, execution on the company's "Pathway of Purpose" strategy, further AI-related collaborations, and valuation, which has moved above the historical median after the rally. As always, these are informational considerations rather than investment recommendations. From what I see, the improving booking trends merit close attention in the quarters ahead.
Using AI Tools for Deeper Stock Insights
In my research process, I frequently rely on Tickeron's AI capabilities to add a data-driven layer to fundamental analysis. The Trending AI Robots page highlights top-performing automated strategies across thousands of tickers, offering a focused view of bots generating real-time interest that can complement traditional research on names like CRL.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CRL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CRL turned positive on September 25, 2026. Looking at past instances where CRL's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 24, 2026. You may want to consider a long position or call options on CRL as a result. In 55 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRL advanced for three days, in 199 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 134 of 213 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for CRL moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 22 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 68 cases where CRL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
CRL broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.953) is normal, around the industry mean (72.578). CRL has a moderately high P/E Ratio (577.050) as compared to the industry average of (146.993). Projected Growth (PEG Ratio) (0.122) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (3.340) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of laboratory testing and research services on a contract basis
Industry MedicalSpecialties
Advertisement